IL2RB: A Potential Drug Target and Biomarker for Cancer, Autoimmune Disorders and Obesity

Target Name: IL2RB

NCBI ID: G3560

IL2RB

IL2RB: A Potential Drug Target and Biomarker for Cancer, Autoimmune Disorders and Obesity

IL2RB (Interleukin-2 Receptor B) is a protein that is expressed in various tissues throughout the body, including the immune system, skin, and tissues. It is a key regulator of immune responses and has been implicated in a number of diseases, including cancer, autoimmune disorders, and obesity.

Recent studies have identified IL2RB as a potential drug target and biomarker for a number of diseases. In this article, we will explore the biology and potential therapeutic applications of IL2RB in more detail.

The biology of IL2RB

IL2RB is a type of cytokine (a protein that is derived from the cytoplasm of cells) that is expressed in various tissues throughout the body. It is a member of the IL2 receptor family, which includes several other cytokines, including IL-1, IL-2, and IL-3. These cytokines play important roles in regulating immune responses and have been implicated in a number of diseases, including cancer, autoimmune disorders, and obesity.

IL2RB is involved in the regulation of immune cell function and in the development of cancer. It has been shown to promote the growth and survival of cancer cells and has been linked to the development of several types of cancer, including breast, ovarian, and prostate cancer.

IL2RB is also involved in the regulation of inflammation and has been shown to contribute to the development of autoimmune disorders. These disorders can cause a range of symptoms, including joint inflammation, skin rashes, and fatigue.

Potential therapeutic applications of IL2RB

Several studies have identified IL2RB as a potential drug target and biomarker for a number of diseases. One of the main targets for IL2RB is the treatment of cancer.

IL2RB has been shown to promote the growth and survival of cancer cells and has been linked to the development of several types of cancer, including breast, ovarian, and prostate cancer. Therefore, IL2RB may be a useful target for the development of cancer therapies that target this protein.

IL2RB has also been identified as a potential biomarker for cancer. Several studies have shown that IL2RB levels are elevated in the blood and lymph fluid of patients with cancer, and that these levels can be used as a diagnostic marker for cancer. Additionally, IL2RB has been shown to be associated with the development of certain types of cancer, such as breast cancer, and may be a useful biomarker for the diagnosis and treatment of these cancers.

IL2RB is also potential target for treating autoimmune disorders. Autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis, are characterized by the immune system attacking the body's own tissues.

IL2RB has been shown to contribute to the development and progression of autoimmune disorders. Therefore, IL2RB may be a useful target for the development of therapies that treat these disorders.

IL2RB may also be a potential target for treating obesity. Obesity, a condition that is characterized by excess body weight, is a major risk factor for a range of diseases, including cardiovascular disease, diabetes, and certain types of cancer.

IL2RB has been shown to contribute to the development and progression of obesity. Therefore, IL2RB may be a useful target for the development of therapies that treat obesity.

Conclusion

IL2RB is a protein that is expressed in various tissues throughout the body and is involved in the regulation of immune cell function and the development of cancer, autoimmune disorders, and obesity. Several studies have identified IL2RB as a potential drug target and biomarker for a number of diseases, including cancer, autoimmune disorders, and obesity. Further research is needed to fully understand the role of IL2RB in these diseases and to develop effective therapies that target this protein.

Protein Name: Interleukin 2 Receptor Subunit Beta

Functions: Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15 (PubMed:15123770, PubMed:31040185)

The "IL2RB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL2RB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets